Alain Matthey

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Sélidji Todagbé Agnandji, Angela Huttner, Madeleine E. Zinser et al. · New England Journal of Medicine · 2015 · 404 citations · Full text

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

Angela Huttner, Julie-Anne Dayer, Sabine Yerly et al. · The Lancet Infectious Diseases · 2015 · 276 citations

Vaccination, Vaccine Safety, Vaccinology +9

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients

François Curtin, Claudia Guebelin, Claire Bridel et al. · Multiple Sclerosis Journal · 2014 · 65 citations

Impact of <i>CYP2D6</i> Functional Allelic Variations on Phenoconversion and Drug–Drug Interactions

Flavia Storelli, Alain Matthey, Sébastien Lenglet et al. · Clinical Pharmacology & Therapeutics · 2017 · 59 citations

Molecular Pharmacology, Pharmacological Study, Biochemistry +14

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients — A twelve month follow-up

François Curtin, Claudia Guebelin, Claire Bridel et al. · Journal of Neuroimmunology · 2015 · 44 citations

Multiple Sclerosis Patients, Autoimmune Disease, Medicine +14